Cargando…
Monitoring vascular normalization: new opportunities for mitochondrial inhibitors in breast cancer
Preclinical evidence indicates the potential of targeting mitochondrial respiration as a therapeutic strategy. We previously demonstrated that mitochondrial inhibitors’ efficacy was restricted to a metabolic context in which mitochondrial respiration was the predominant energy source, a situation ac...
Autores principales: | Mouron, Silvana, Bueno, Maria J., Muñoz, Manuel, Quintela-Fandino, Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018703/ https://www.ncbi.nlm.nih.gov/pubmed/33869665 http://dx.doi.org/10.18632/oncoscience.523 |
Ejemplares similares
-
Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach
por: Bueno, Maria J, et al.
Publicado: (2017) -
Monitoring vascular normalization induced by antiangiogenic treatment with 18F‐fluoromisonidazole‐PET
por: Hernández-Agudo, Elena, et al.
Publicado: (2015) -
p27(Kip1) V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer
por: Mouron, Silvana, et al.
Publicado: (2023) -
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
por: Mouron, Silvana, et al.
Publicado: (2021) -
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
por: Quintela-Fandino, Miguel, et al.
Publicado: (2019)